Related by context. All words. (Click for frequent words.) 74 Phase III Clinical Trial 74 acetonide FA 73 Personalized Immunotherapy 73 Meets Primary Endpoint 73 oral prodrug 72 Methylnaltrexone 72 Diabetic Neuropathy 72 Phase 2b Clinical Trial 72 induced macular edema 72 Phase 2a Clinical Trial 72 JAK Inhibitor 72 acute peripheral arterial 71 Pivotal Study 71 Pivotal Trial 71 Diabetic Macular Edema 71 Novel Oral 71 Safinamide 71 Receives Orphan Drug Designation 71 Tezampanel 71 Combination REOLYSIN R 70 Investigational Treatment 70 Drug Candidate 70 vitreoretinal disorders 70 Vascugel 70 Pivotal Phase 70 Hsp# Inhibitor 70 CYT# potent vascular disrupting 70 II Clinical Trial 70 Patients Treated With 70 NAVISTAR R 70 trial evaluating PRX# 70 Tasimelteon 70 Granulocyte Colony Stimulating Factor 70 phase IIb trial 70 Phase III Trial 70 Achieves Primary Endpoint 70 Completes Patient Enrollment 70 Pafuramidine 70 Pivotal Phase III 70 FOLOTYN ® 70 PEGylated Fab fragment 70 Prospective Randomized 70 Initiates Phase II 70 Efficacy Trial 70 fosbretabulin 70 Oral Fingolimod 70 JAK inhibitor 70 Phase IIb Clinical Trial 70 Cetrorelix 70 INTEGRILIN R 70 Phase III Pivotal 70 catheter occlusion 70 Initiate Clinical Trial 69 2 methoxyestradiol 69 treat benign prostatic 69 Vidaza azacitidine 69 IL# PE#QQR 69 Civacir 69 receptor tyrosine kinase inhibitor 69 Golimumab 69 Ranolazine 69 OMNARIS HFA 69 targeted radiotherapeutic 69 Pivotal Clinical Trial 69 SNT MC# 69 Friedreich Ataxia FRDA 69 Transdermal Patch 69 SinuNase TM 69 Tolvaptan 69 Demonstrates Efficacy 69 Dupuytren Contracture 69 Initiates Clinical Trial 69 Factor VIIa 69 SUTENT ® 69 Elagolix 69 Investigational Compound 69 Dapagliflozin 69 thetreatment 69 delivers fluocinolone acetonide FA 69 Ridaforolimus 69 Enzyme Replacement Therapy 69 Antitumor Activity 69 diarrhea predominant irritable 69 Natalizumab 69 Bazedoxifene 69 Diabetic Macular Edema DME 69 investigational humanized monoclonal antibody 69 Pooled Analysis 69 Archexin 69 Dasatinib 69 hyperphenylalaninemia HPA due 69 INCB# [003] 69 orally administered inhibitor 69 Pegloticase 69 Overactive Bladder 69 plasma kallikrein inhibitor 69 LEUKINE 69 Granted Orphan Drug 69 Aviptadil 69 phase IIb clinical 69 Clinical Trial Results 69 Randomized Study 69 Phase #b/#a clinical 69 Phase IIb Trial 69 invasive candidiasis 69 AA Amyloidosis 68 Deforolimus 68 metaglidasen 68 Rilonacept 68 Eculizumab 68 Oral Calcitonin 68 Degarelix 68 relapsing remitting MS RRMS 68 HDAC Inhibitor 68 Phase III Clinical Trials 68 CTAP# Capsules 68 Squalamine 68 Myocet 68 ACV1 68 Completes Enrollment 68 NDA Submission 68 Mipomersen 68 lexidronam injection 68 TNF Tumor Necrosis Factor 68 Patient Enrollment 68 Interferon Beta 68 Fondaparinux 68 oral dual endothelin 68 MKC# MKC# PP 68 forodesine 68 Plasmin 68 FASLODEX 68 Preclinical Efficacy 68 Ceflatonin R 68 Serostim ® 68 SNT-MC#/idebenone 68 dyskinesia PD LID 68 nucleoside analog 68 Aflibercept 68 docetaxel Taxotere ® 68 Resten NG 68 retinal vein occlusion induced 68 Pirfenidone 68 methylnaltrexone bromide 68 Ozarelix 68 Randomized Double blind 68 Kamada AAT 68 Lupus Nephritis 68 Octreotide 68 CEQ# 68 AEG# 68 vidofludimus 68 Tiotropium 68 oral beclomethasone dipropionate 68 sorafenib tablets 68 intranasal formulation 68 topically applied SEPA 68 Phase 2a Trial 68 RezularTM 68 brand ciclesonide HFA 68 novel VDA molecule 68 Cannabinor 68 vapreotide acetate 68 pan HDAC inhibitor 68 octreotide implant 68 Recombinant Human 68 Parathyroid Hormone 68 BAL# [002] 68 Zorbtive TM 68 phase IIa clinical 68 thrombolytic agent 68 Placebo Controlled Trial 68 Renal Cell Carcinoma 68 Prolongs Survival 68 DU #b 67 Catena ® 67 Acute Ischemic Stroke 67 Genasense ® 67 Pulmonary Arterial Hypertension 67 Lubiprostone 67 microplasmin 67 Teriparatide 67 Initiates Phase III 67 diabetic macular edema DME 67 Sapacitabine 67 MIVI III 67 hypervascular tumors 67 Carfilzomib 67 davunetide intranasal AL 67 GW# [003] 67 Initiates Enrollment 67 Phase IIIb clinical 67 Chrysalin 67 Phase 2b Trial 67 mGluR5 negative 67 Calcitonin 67 riociguat 67 liposomal formulation 67 postoperative ileus 67 PEGylated anti 67 Preclinical Data 67 Cethrin R 67 dihydrochloride Tablets 67 Successfully Completes Phase 67 Refractory Angina 67 metastatic neuroendocrine tumors 67 EVIZON TM 67 PAOD 67 ThermoDox R 67 GEM OS2 67 YONDELIS 67 acyclovir Lauriad R 67 constipation OIC 67 Randomized Phase 67 Chronic Sinusitis 67 RhuDex ® 67 MYCAMINE 67 biliary tract cancer 67 Talabostat 67 Bosutinib 67 candidates Azedra TM 67 sapropterin dihydrochloride Tablets 67 Fibrin Pad 67 Hepatocellular Carcinoma HCC 67 Motesanib 67 Fabry Disease 67 Naive Patients 67 EXPAREL TM 67 Shows Efficacy 67 Ophena 67 Long Term Efficacy 67 Central Retinal Vein 67 Alfimeprase 67 Mg Usa 67 Tocilizumab 67 Valsartan 67 Anti VEGF 67 Parkinson disease levodopa induced 67 PROSTASCINT R 67 Cethromycin 67 Study Evaluating 67 LibiGel ® 67 ADP receptor antagonist 67 ALN TTR# 67 vinca alkaloid 67 R Saizen R 67 mertansine 67 Candesartan 67 including eniluracil ADH 67 Alzheimer disease cognitive impairment 67 Patients Receiving 67 Deferiprone 67 topically administered 67 Desvenlafaxine 67 Enzastaurin 67 severe gastroparesis 67 Fingolimod 67 Treatment Resistant 67 Leber Hereditary Optic Neuropathy 67 Randomized Clinical Trial 67 Wafer polifeprosan 67 INCB# [001] 67 Advanced Melanoma 67 Demonstrates Positive 67 CCR9 antagonist 67 Vitrasert R 67 DDP# 67 Silodosin 67 post operative ileus 67 Traficet EN 67 Nilotinib 67 compound AEOL # 67 Glufosfamide 67 Atypical Hemolytic Uremic Syndrome 67 Intravitreal 67 Trial Evaluating 67 Medoxomil 67 Solazed TM 67 R lenalidomide 67 Metastatic Melanoma 67 Lixivaptan 67 budesonide foam 67 IRX 2 67 Tyrosine Kinase Inhibitor 67 Ozurdex 67 Xanafide 67 CCX# B 67 kidney urologic 66 Liprotamase 66 Mg Uk 66 Hepatocellular Carcinoma 66 Fibrillex TM 66 Xcytrin R 66 Octreolin 66 6R BH4 66 benign prostatic hypertrophy BPH 66 Tacrolimus 66 SPRYCEL ® 66 Complicated Skin 66 HeFH 66 unique alkylating agent 66 eprotirome 66 HQK 66 selective modulator 66 Irinotecan 66 LHRH antagonists 66 Fludara ® 66 Files IND 66 Pazopanib 66 Percutaneous Transluminal Coronary Angioplasty 66 Ophena TM 66 inhaled formulation 66 Adjuvant Treatment 66 rALLy clinical trial 66 Pimavanserin 66 Ciclesonide 66 Panzem R 66 Bucindolol 66 Iluvien ® 66 Benign Prostatic Hyperplasia BPH 66 huC# DM4 66 C1 Inhibitor 66 Rheumatoid Arthritis RA 66 fibrotic disease 66 superficial bladder cancer 66 LymphoStat B belimumab 66 Anthracycline 66 investigational monoclonal antibody 66 Demonstrates Significant 66 Initiates Clinical 66 CB2 selective receptor agonist 66 Pathway Inhibitor 66 Immunotherapeutic 66 TELINTRA 66 ALVESCO ® 66 BENLYSTA ® 66 either acutely decompensated 66 ORENCIA R 66 Oral Mucositis 66 Icatibant 66 Ranibizumab 66 MAGE A3 ASCI 66 ZOLINZA 66 Azedra 66 TPI ASM8 66 Pertuzumab 66 dual endothelin receptor antagonist 66 Campath ® 66 tiapamil 66 lomitapide 66 cinacalcet 66 occlusion PAO 66 BRIM2 66 Angioedema 66 Transdermal Delivery 66 recurrent glioblastoma multiforme 66 Tanespimycin 66 Replacement Therapy 66 Ecallantide 66 Tesetaxel 66 Retinoic Acid 66 Presents Positive 66 Amrubicin 66 CA4P 66 Hypercholesterolemia 66 oropharyngeal candidiasis 66 Romiplostim 66 Androxal TM 66 Trandolapril 66 Orally administered 66 PDE4 inhibitor 66 mu opioid receptor antagonist 66 INSPIRE Trial Phase III 66 Benign Prostatic Hyperplasia 66 Phase IIIb 66 Vandetanib 66 Thiazolidinediones 66 PresbyLens ® 66 anterior uveitis 66 r hGH 66 Losartan 66 Controlled Study 66 Phase IIB 66 NV1FGF 66 Monotherapy 66 drug ISA# 66 Maribavir 66 BCG refractory carcinoma 66 medically refractory 66 MEK Inhibitor 66 Regenerative Cells 66 Aurora Kinase 66 TG# [003] 66 herpetic keratitis 66 HCV protease inhibitor 66 Chronic Heart Failure 66 etanercept Enbrel 66 Sevelamer 66 Dacogen injection 66 Efficacy Results 66 Initiate Phase II 66 Occlusive Disease 66 Anti Tumor Activity 66 CCR5 antagonist 66 inhibitor RG# 66 AAG geldanamycin analog 66 PGL# 66 Proxinium TM 66 Kuvan TM sapropterin 66 Chronic Hepatitis C 66 PNP inhibitor 66 Hormone Refractory Prostate Cancer 66 Pharmacokinetics PK 66 Tigecycline 66 treat chronic sinusitis 66 Entereg R 66 multicenter Phase II 66 polycythemia vera essential thrombocythemia 66 IMA# 66 refractory gout 66 NMDA antagonist 66 Intravesical 66 acting injectable formulation 66 PDX pralatrexate 66 cell lymphoma CTCL 66 Biolimus A9 66 Afatinib 66 Phase III Trials 66 BARACLUDE R 66 iobenguane 66 beta 1a 66 PSN# [002] 66 Renal Impairment 66 lucinactant 66 edifoligide 66 Myelodysplastic Syndrome MDS 66 RNAi therapeutic targeting 66 Initiate Phase 66 Denufosol 66 PROMACTA 66 dihydrochloride 66 Augment TM 66 Initiates Clinical Trials 66 taxane resistant 66 Single Dose 66 cMET 66 TRO# 66 occlusion CRVO 66 Advanced Renal Cell 66 KRN# 66 Prestara 66 Saforis 66 Aliskiren 66 Phase IIb clinical trials 66 SomatoKine 66 Tesamorelin 66 Renal Artery 66 omega interferon 66 cardio renal 65 EndoTAG TM -1 65 Inhalation Solution 65 placebo controlled clinical 65 Ocrelizumab 65 Plecanatide 65 Zenvia ™ 65 lanreotide 65 sapropterin dihydrochloride 65 GTC recombinant human 65 evaluating picoplatin 65 CIMZIA TM certolizumab pegol 65 hypoxia activated prodrug 65 choroidal neovascularization 65 SUPPRELIN R LA 65 icatibant 65 Endologix Powerlink System 65 Cardiotoxicity 65 VAPRISOL 65 REG1 65 Patients Suffering 65 placebo controlled Phase III 65 Metastatic Colorectal Cancer 65 CIMZIA ™ 65 Peripheral Arterial 65 R#/MEM 65 allosteric modulator NAM 65 urethral bulking agent 65 Trodusquemine MSI 65 samarium Sm 65 direct thrombin inhibitors 65 essential thrombocythemia ET 65 Lymphocytic 65 Patients Treated 65 Clolar ® 65 complement inhibitor eculizumab 65 Bepreve TM 65 Voreloxin 65 ulimorelin 65 CDP# 65 Vicriviroc 65 molecular imaging radiopharmaceutical 65 humanized monoclonal 65 peripherally acting 65 Aryplase 65 CRMD# 65 Hedgehog Pathway Inhibitor 65 OZURDEX ® 65 Phase 2b Study 65 OMNARIS Nasal Spray 65 retinal vein occlusion 65 noninfectious uveitis 65 Cypher Sirolimus 65 Relapsed Multiple Myeloma 65 Cx# [002] 65 Phase 2a Study 65 SPIRIVA ® 65 Indaflex TM 65 IV Busulfex 65 Tumor Response 65 lorvotuzumab mertansine 65 ATL# [002] 65 myelofibrosis polycythemia vera 65 Randomized Phase II 65 Everolimus 65 toenail onychomycosis 65 Exherin TM 65 MKC# MT 65 Dupuytren Disease 65 Kuvan R 65 Neovascular AMD 65 topical ophthalmic 65 Vimpat R 65 oropharyngeal candidiasis OPC 65 LHON 65 chronic eosinophilic leukemia 65 Tyrima 65 GAMMAGARD 65 Severe Sepsis 65 CIMZIA R 65 vascular disrupting agent 65 sodium thiosulfate STS 65 EXPAREL ™ 65 Phase Ib II 65 Lisofylline 65 Oracea TM 65 castrate resistant prostate cancer 65 virus HCV protease inhibitor 65 Neulasta ® 65 candidates Azedra 65 uricase 65 systemic immunosuppressive drugs 65 neovascular age 65 hyaluronidase enzyme 65 HuMax EGFr 65 Febuxostat 65 Submits NDA 65 rusalatide acetate 65 gastrointestinal stromal tumors GIST 65 Well Tolerated 65 AzaSite Plus 65 BRAF inhibitor 65 canakinumab 65 opioid induced bowel dysfunction 65 Dalbavancin 65 Fx #A 65 bevacizumab Avastin ® 65 Prostacyclin 65 Rivaroxaban 65 fenretinide 65 itraconazole Sporanox 65 p# inhibitor 65 5 HT6 receptor 65 Embolization 65 post herpetic neuralgia PHN 65 Phase Ib clinical 65 Immunosuppressant 65 PRT# 65 oral ridaforolimus 65 Antigen Specific 65 pseudobulbar affect PBA 65 Phase 2a 65 investigational pharmacologically unique 65 Refractory Hodgkin Lymphoma 65 Kepivance 65 delivery polymer matrix 65 Onalta ™ 65 denileukin diftitox 65 Improves Outcomes 65 hypereosinophilic syndrome 65 Zileuton 65 familial amyloidotic polyneuropathy FAP 65 Neovascular Age Related Macular 65 cannabinor 65 Preclinical Study 65 Elocalcitol 65 Embolic Protection 65 MGd 65 Cutaneous T 65 immunomodulatory therapy 65 PHX# 65 First Patient Enrolled 65 Catheter Associated 65 neovascular 65 Antitumor 65 Telbivudine 65 Investigational Agent 65 GABITRIL 65 Cerebril TM 65 drug zotarolimus 65 TYSABRI natalizumab 65 MTP inhibitor 65 Ketorolac 65 Tracleer R 65 non nucleoside inhibitor 65 Diabetic Foot Ulcer 65 ACOMPLIA R 65 Fodosine 65 prokinetic agent 65 Pemetrexed 65 unresectable tumors 65 IMiDs ® 65 AA amyloidosis 65 Polyneuropathy 65 Diamyd R 65 IMiDs ® compound 65 Therapeutic Vaccine 65 HDL Selective Delipidation 65 Abbokinase 65 developing Bicifadine serotonin 65 Heart Transplant Recipients 65 TREDAPTIVE 65 Systemic Delivery 65 highly selective inhibitor 65 myelodysplastic myeloproliferative diseases 65 Epratuzumab 65 synthetic retinoid 65 TBC# 65 Enkephalin 65 interferon gamma 1b 65 PEG SN# 65 Onalta 65 Clinical Trial Evaluating 65 ZEVALIN ® 65 keloid scarring 65 sodium glucose cotransporter 65 TACI Ig 65 Gel repository corticotropin injection 65 Dose Escalation 65 Desmoteplase 65 FDA Approvals 65 Ambrisentan 65 Boceprevir 65 Onychomycosis 65 ThGRF 65 Presents Preclinical Data 65 Sitagliptin 65 ILUVIEN ® 65 RhuDex 65 First Patient Dosed 65 Familial Adenomatous Polyposis FAP 65 sunitinib malate 65 Receives Orphan Drug 65 macular edema secondary 65 PEGylated interferon beta 1a 65 Sym# 65 ONCONASE R 65 SPL# Gel vaginal microbicide 65 oral FTY# 65 Oral Insulin 65 ospemifene 65 ELACYT 65 Vidofludimus 65 Cancidas 65 Alocrest 65 EVIZON 65 Tavocept 65 topical gel formulation 65 Pegylated Interferon 65 Fidaxomicin 65 Bicalutamide 65 Mitoxantrone 65 personalized cellular immunotherapy 65 prostate TURP 65 2A receptor agonist 65 angiogenesis inhibitor 65 rhIGF-I/rhIGFBP-3 65 rNAPc2 65 EnteroMedics proprietary neuroblocking technology 65 OHR/AVR# 65 Opterone R 65 selective immunoproteasome inhibitor 65 systemically administered 65 Virulizin ® 65 rheumatoid arthritis osteoarthritis ankylosing 65 Heart Failure Patients 65 Abciximab 65 Pagoclone 65 dextofisopam 65 Palonosetron 65 Bevacizumab 65 Genasense ® oblimersen 65 Oral Spray 65 Ganciclovir 65 Secondary Hyperparathyroidism 65 RLY# 65 Intravitreal injections 65 Temsirolimus 65 CINQUIL 65 Present Preclinical Data 65 Hepatitis C Virus HCV 65 VIVITROL ® 65 KL4 Surfactant 65 Romidepsin 65 Cleviprex TM clevidipine 65 Glatiramer Acetate 65 Microspheres 65 PRTX 65 hyperplasia BPH 65 albiglutide 65 Aganocide 65 Left Ventricular 65 Proquin XR 65 oral rivaroxaban 65 TH# [003] 65 histamine dihydrochloride 65 product platforms AZX# 65 idiopathic thrombocytopenic purpura ITP 65 Restenosis 65 Omacetaxine 64 Cellegesic 64 Inhalation Aerosol 64 INTEGRILIN 64 Novolimus 64 Controlled Trial 64 Announces Poster Presentations 64 Chemokine Receptor 64 FDA Accepts 64 teriflunomide 64 Retisert TM 64 BrachySil TM 64 pharmacokinetic PK study 64 Interferon Alpha 64 Peginterferon alfa 2b 64 tezampanel 64 investigational oral inhibitor 64 Vernakalant 64 aerosolized AAT 64 rilonacept 64 ocular formulation 64 somatostatin analog 64 brimonidine 64 candesartan cilexetil 64 somatostatin analogues 64 transplantation HCT 64 Allergic Rhinitis 64 Daclizumab 64 ATTR CM 64 cathepsin K inhibitor 64 tiuxetan 64 intravascular hemolysis 64 includes Dideco CarboMedics 64 Randomized Evaluation 64 sulodexide 64 Muraglitazar 64 Frozen Shoulder syndrome Adhesive 64 Curaxin CBLC# 64 HuMax TAC 64 Multicenter Randomized 64 Bezielle 64 squalamine 64 sorafenib Nexavar 64 oral salmon calcitonin 64 Alemtuzumab 64 CCX# 64 protein tyrosine phosphatase 1B 64 Eluting Stent 64 dextromethorphan quinidine 64 Cytarabine 64 luliconazole 64 Infected Patients 64 ACTEMRA TM 64 Lu AA# 64 sapacitabine CYC# 64 fluocinolone acetonide 64 Nexavar ® 64 Soliris eculizumab 64 Nitazoxanide 64 chronic myocardial ischemia 64 thalidomide Thalomid 64 Dyskinesia 64 ancrod 64 Vascular Disrupting Agent 64 Treatment Shows Promise 64 MEK inhibitor 64 confirmatory Phase III 64 Pegylated 64 ESBA# 64 Parathyroid hormone 64 hormone LHRH antagonist 64 Platelet Inhibition 64 SERMs 64 Topiramate 64 VA# [002] 64 interferon beta therapy 64 Altastaph 64 Inhaled nitric oxide 64 P#X# antagonist 64 motexafin gadolinium Injection 64 humanized anti 64 induce orthostatic hypotension 64 small molecule thrombopoietin 64 posterior uveitis 64 Ostarine 64 brivaracetam 64 orally inhaled migraine 64 Gliadel R 64 Prodarsan R 64 phase IIa 64 Pivotal Trials 64 velafermin 64 Systemic Sclerosis 64 AFREZZA TM 64 Besivance 64 Melphalan 64 novel oral anticoagulant 64 gastrointestinal disorders ATI 64 TRAIL receptor antibodies 64 Indomethacin 64 TLK# 64 Nexavar sorafenib 64 Preclinical studies suggest 64 Sanvar R 64 ORENCIA ® 64 candidate Zenvia 64 Orphan Status 64 Dacogen decitabine 64 antiplatelet agent 64 Mitomycin C 64 Mycophenolate Mofetil 64 targeted antifolate 64 HCV Protease Inhibitor 64 BiovaxID TM 64 mGluR2 positive 64 XYOTAX TM 64 overactive bladder syndrome 64 Adult Stem Cell Therapy 64 Chemophase 64 Myolimus 64 Epoprostenol 64 Ganite ® 64 Pemphigus Vulgaris 64 EOquin TM 64 BYETTA ® 64 Dermylex TM 64 Phase IIa trials 64 CIPN 64 CTAP# 64 terlipressin 64 DAPT 64 Bronchiectasis 64 Manja Bouman CEO 64 Varespladib 64 Nebulized 64 STRIDE PD 64 Bone Graft 64 Catheter Ablation 64 CINTREDEKIN BESUDOTOX 64 miconazole Lauriad ® 64 pralatrexate injection folate analogue 64 catheter occlusion CO 64 QUADRAMET R 64 Protelos 64 BAY #-# 64 subependymal giant cell 64 atypical Hemolytic Uremic Syndrome 64 AGGRASTAT R Injection tirofiban 64 Ischemic 64 QLT# 64 DermaVir Patch 64 alvimopan 64 vitreous floaters 64 Autologous Stem Cell Transplantation 64 Resistant Hypertension 64 multi kinase inhibitor 64 Phase IIb trials 64 Nonalcoholic Steatohepatitis 64 Previously Treated 64 Liposomal 64 IMiDs R 64 systemic fungal infections 64 Avanafil 64 octreotide acetate 64 Zalypsis 64 nephropathic cystinosis 64 ocular inflammatory 64 TG MV 64 Syncria R 64 RECOTHROM R 64 Phase IIa trial 64 AVAPRO 64 Dose Ranging Study 64 afamelanotide 64 Ketotransdel 64 generation purine nucleoside 64 AGILECT R 64 JAK1 64 SUTENT 64 hematological indications 64 Disease IBD 64 Myelofibrosis 64 Shows Promising 64 ARIXTRA R 64 HCV NS5B polymerase 64 Phase 2a clinical 64 Recurrent Breast Cancer 64 PEGINTRON TM 64 CRVO 64 external counterpulsation systems 64 Drug Shows Promise 64 Teriflunomide 64 atypical hemolytic uremic syndrome 64 Anti Tumor 64 LEP ETU 64 Systemic Juvenile Idiopathic 64 Disease Progression 64 Vidaza ® 64 Lenalidomide 64 Beta Blocker 64 Polyphenon ® E 64 malignant ascites 64 alkylating agent 64 Factor Receptor 64 Mouse Model 64 Metabolic Disorder 64 PI3K/Akt pathway inhibitor 64 Phase 1b trial 64 Neuroprotective Effects 64 selective androgen receptor modulator 64 Sangamo BioSciences Announces 64 By JENNIFER LEARN 64 nucleotide analogue 64 HepaSphere 64 FDA APPROVES 64 Metastatic Prostate Cancer 64 Adalimumab 64 RNAi Therapeutics 64 vitreomacular traction 64 Perforomist ™ Inhalation Solution 64 Laquinimod 64 Ribavirin causes 64 Pyridorin 64 Behcet uveitis 64 RELOVAIR ™ 64 radezolid 64 Actimmune ® 64 LEVADEX TM 64 Locteron ® 64 systemic anaplastic large 64 orally inhaled 64 ALN TTR 64 Clinical Trial Data 64 Alagebrium 64 JAK2 Inhibitor 64 Azathioprine 64 Noxafil 64 p# biomarker 64 Malignant Melanoma 64 symptomatic benign prostatic 64 CR# vcMMAE 64 Is Well Tolerated 64 de novo kidney transplant 64 Receptor Agonist 64 Pralatrexate 64 topical formulations 64 Tracleer r 64 CYPHER R Sirolimus Eluting 64 Thrombus 64 Interferon alpha 64 selective androgen receptor modulators 64 BEMA TM Fentanyl 64 relapsing multiple sclerosis 64 SEROQUEL R 64 Firazyr 64 factor Xa 64 candidate epratuzumab 64 STELARA TM 64 immune modulator 64 Zirgan 64 metastatic malignant 64 Peginterferon 64 glucokinase activator 64 huN# DM1 64 acute mania 64 DURIN TM 64 Eltrombopag 64 Cholesterol Lowering Drug 64 acute PAO 64 dosage regimens 64 Akt inhibitor 64 Gastrointestinal Stromal Tumors